Cartagena Protocol on Biosafety

The Cartagena Protocol on Biosafety is a supplementary agreement to the Convention on Biological Diversity (CBD), adopted in Montréal on 29 January 2000 and entering into force on 11 September 2003 after the fiftieth instrument of ratification was deposited. Its legal mandate flows directly from CBD Article 19(3), which directed Parties to consider the need for a protocol setting out procedures in the field of the safe transfer, handling, and use of any living modified organism (LMO) resulting from modern biotechnology that may have an adverse effect on biological diversity. Negotiations began with an Open-ended Ad Hoc Working Group on Biosafety established in 1996; the failure to conclude at the Cartagena, Colombia, extraordinary meeting of the Conference of the Parties in February 1999 lent the instrument its name, though the final text was sealed eleven months later in Montréal. The Protocol is explicitly anchored in the precautionary approach reflected in Principle 15 of the 1992 Rio Declaration, which is restated in its Article 1 (objective) and operationalized in Articles 10(6) and 11(8).

The Protocol's central operative mechanism is the Advance Informed Agreement (AIA) procedure, set out in Articles 7 through 10. Before the first intentional transboundary movement of an LMO destined for introduction into the environment of the importing Party—seeds for planting, fish for release, microorganisms for bioremediation—the Party of export, or the exporter, must notify the competent national authority of the Party of import in writing. The notification must contain the detailed information specified in Annex I, including the taxonomic identity of the recipient organism, the donor organism, the inserted nucleic acid, and an accompanying risk assessment. The importing Party must acknowledge receipt within ninety days and communicate its decision—approval, approval with conditions, prohibition, or a request for further information—within 270 days. Article 12 permits an importing Party to review and change a decision in light of new scientific information.

A critical distinction within the Protocol is that the AIA procedure does not apply to every LMO. Under Article 11, LMOs intended for direct use as food or feed, or for processing (the so-called LMO-FFPs, such as commodity grain shipments of genetically modified maize or soybean), follow a streamlined procedure: a Party that takes a domestic decision to authorize such an LMO for placing on the market must inform other Parties through the Biosafety Clearing-House within fifteen days. Importing Parties may then regulate under their own domestic frameworks, and a developing-country Party lacking such a framework may declare that decisions will be taken under a national regulatory regime consistent with the Protocol's objective. The Protocol also exempts pharmaceuticals for humans addressed by other international agreements (Article 5) and LMOs in transit or destined for contained use (Article 6).

India ratified the Protocol on 17 January 2003, and it implements obligations through the Environment (Protection) Act, 1986 and the 1989 Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms, administered by the Genetic Engineering Appraisal Committee under the Ministry of Environment, Forest and Climate Change. The European Union transposed Protocol obligations through Regulation (EC) No 1946/2003. The Nagoya–Kuala Lumpur Supplementary Protocol on Liability and Redress, adopted on 15 October 2010 and entering into force on 5 March 2018, addresses response measures for damage to biodiversity caused by LMOs—closing a gap left by Article 27 of the original text. The governing body is the Conference of the Parties serving as the Meeting of the Parties (COP-MOP), which has met alongside CBD COPs in venues including Nagoya (2010), Pyeongchang (2014), and Cancún (2016).

The Cartagena Protocol must be distinguished from the Nagoya Protocol on Access and Benefit-Sharing, adopted in 2010, which governs genetic-resource access and the equitable sharing of benefits rather than biosafety; both are protocols to the same parent CBD but address wholly different subject matter. It also differs from the Codex Alimentarius food-safety standards and from the World Trade Organization's Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement), which assess risk to human health and trade rather than to biological diversity. The Protocol's preamble deliberately states that it shall not be interpreted as subordinate to other agreements while also asserting it does not alter existing rights and obligations—a calculated ambiguity over the trade-environment relationship.

The most enduring controversy concerns the relationship between the Protocol's precautionary stance and WTO trade disciplines, sharpened by the 2006 WTO panel report in EC–Biotech (DS291, DS292, DS293) brought by the United States, Canada, and Argentina against the European Communities' de facto moratorium on biotech approvals. The United States, a leading agricultural-biotechnology exporter, has signed the CBD but never ratified it and is therefore not a Party to the Protocol, which constrains the regime's reach. Documentation requirements under Article 18(2)(a) for LMO-FFP shipments—whether a bill of lading must state "contains" or merely "may contain" living modified organisms—were resolved only at COP-MOP 4 in Bonn in 2008.

For the working practitioner, the Cartagena Protocol is the principal multilateral instrument structuring how states lawfully refuse, condition, or accept imports of genetically modified seeds and grain, and it furnishes the legal vocabulary—AIA, LMO, risk assessment under Annex III, the Biosafety Clearing-House—that recurs in domestic biotechnology regulation worldwide. Desk officers handling agricultural trade disputes, environment negotiators preparing for CBD COPs, and analysts assessing a state's compliance posture must read the Protocol alongside its Supplementary Protocol on liability and the relevant SPS jurisprudence to map where precaution and trade law intersect.